Oxigene Inc (OXGN) 1.61 $OXGN
OXiGENE Announces Presentation and Webcast at the 17th Annual BIO CEO & Investor Conference on February 10th
GlobeNewswire - Mon Jan 26, 3:15PM CST
OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel cancer therapeutics, announced that David Chaplin, Ph.D., president and chief executive officer, will provide a corporate overview at the 17th Annual BIO CEO & Investor conference on February 10, 2015. The presentation will take place at 10:30 a.m. ET at the Waldorf Astoria Hotel in New York City.
OXGN: 1.61 (+0.01)
Biotech Stock Mailbag: Aethlon Medical, Oxigene, Sarepta
at The Street - Fri Dec 05, 5:00AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care.
OXGN: 1.61 (+0.01), BMRN: 100.76 (+1.98), RNA: 18.65 (unch), SRPT: 12.76 (+0.11)
OXiGENE Announces Preclinical Poster Presentation on OXi4503 at Upcoming American Society of Hematology Meeting
GlobeNewswire - Thu Nov 20, 7:00AM CST
OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing novel cancer therapeutics, today announced that a poster presentation related to its clinical stage product candidate, OXi4503, will be presented at the American Society of Hematology (ASH) annual meeting taking place December 6-9, 2014 in San Francisco.
OXGN: 1.61 (+0.01)
OXiGENE Announces Issuance of European Patent for OXi4503 in Acute Myeloid Leukemia and other Myeloid Malignancies
GlobeNewswire - Mon Nov 17, 3:00PM CST
OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing novel cancer therapeutics, today announced that the company has been granted a patent by the European Patent Office related to its current clinical product candidate, OXi4503. The patent (EP 2219451 B1) is drawn to the use of OXi4503 in treating non-solid myeloid neoplasm, including acute myeloid leukemia (AML).
OXGN: 1.61 (+0.01)
Hot Stock: OXiGENE, Shares Drop 5.3% (OXGN)
Comtex SmarTrend(R) - Mon Nov 17, 2:41PM CST
OXiGENE (NASDAQ:OXGN) is one of today's worst performing low-priced stocks, down 5.3% to $1.88 on 1.7x average daily volume. Thus far today, OXiGENE has traded 1.3 million shares, vs. average volume of 816,000 shares per day. The stock has underperformed the Dow (-5.3% to the Dow's 0.0%) and underperformed the S&P 500 (-5.3% to the S&P's -0.0%) during today's trading.
OXGN: 1.61 (+0.01)
Which Chemotherapy Should OXiGENE Test Their Zybrestat+Avastin Combo Against?
Clinically Sound Investor - at Seeking Alpha - Mon Nov 17, 10:42AM CST
OXGN: 1.61 (+0.01)
OXiGENE: Q3 Earnings And Avastin Approval, Bull Thesis Reiterated
Trevor Lowenthal - at Seeking Alpha - Fri Nov 14, 3:20PM CST
OXGN: 1.61 (+0.01)
Oxigene: Why I Think This Risky Biotech Is A Speculative Buy
Daniel Ward - at Seeking Alpha - Fri Nov 14, 8:15AM CST
OXGN: 1.61 (+0.01)
OXiGENE (OXGN) CEO Dr. Dave Chaplin on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 12, 8:27PM CST
OXGN: 1.61 (+0.01)
OXiGENE (OXGN) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Wed Nov 12, 3:25PM CST
OXGN: 1.61 (+0.01)
OXiGENE beats by $0.06
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 3:05PM CST
OXGN: 1.61 (+0.01)
OXiGENE Reports Third Quarter 2014 Financial Results
GlobeNewswire - Wed Nov 12, 3:02PM CST
- Positive Data from the Phase 2 GOG 186I Study in Ovarian Cancer Presented at Major Conference -
OXGN: 1.61 (+0.01)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 8:18AM CST
ANV: 0.97 (-0.03), KEP: 20.67 (+0.11), RADA: 2.46 (+0.01), SEAS: 18.83 (+0.03), HPJ: 5.71 (+0.16), PLUG: 3.15 (unch), SUPN: 8.80 (+0.22), NBG: 1.61 (+0.18), GV: 2.45 (+0.02), OXGN: 1.61 (+0.01), NOAH: 21.59 (+0.72), FOSL: 98.44 (-0.30), AEO: 14.68 (-0.12), IBIO: 0.90 (+0.36), MTOR: 14.33 (+0.38), MLNX: 46.35 (+1.47), SUSQ: 13.48 (+0.01)
Oxigene Faces Challenges for Ovarian Cancer Drug Even With Encouraging Data
at The Street - Wed Nov 12, 4:12AM CST
An analysis of results from Oxigene's phase II study of fosbretabulin plus Avastin in recurrent ovarian cancer.
OXGN: 1.61 (+0.01), GSK: 47.94 (+1.99)
Update: OXiGENE Presents Zybrestat/Avastin Data, Bull Thesis Remains Intact
Trevor Lowenthal - at Seeking Alpha - Tue Nov 11, 4:56AM CST
OXGN: 1.61 (+0.01)
Stock to Watch: OXiGENE Down 6.9% (OXGN)
Comtex SmarTrend(R) - Mon Nov 10, 11:59AM CST
OXiGENE (NASDAQ:OXGN) is one of today's worst performing low-priced stocks, down 6.9% to $2.01 on 1.0x average daily volume. Thus far today, OXiGENE has traded 694,000 shares, vs. average volume of 663,000 shares per day. The stock has underperformed the Dow (-6.9% to the Dow's 0.2%) and underperformed the S&P 500 (-6.9% to the S&P's 0.3%) during today's trading.
OXGN: 1.61 (+0.01)
OxiGene presents Phase 2 data on fosbretabulin
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 11:31AM CST
OXGN: 1.61 (+0.01)
Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Pipeline Report 2014 - 32 Companies & 65 DRug Profiles
M2 - Mon Nov 10, 10:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/wml9ch/head_and_neck) has announced the addition of the "Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Shionogi & Co., Ltd. - Amgen Inc. - Eli Lilly and Company - GlaxoSmithKline plc - Celltrion, Inc. - Novartis AG - Eisai Co., Ltd. - ImmunoGen, Inc. - Santaris Pharma A/S - CEL-SCI Corporation - OXiGENE, Inc. - Takara Bio Inc. - Panacea Biotec Limited - PCI Biotech AS - Nanobiotix - Acceleron Pharma, Inc. - Virttu Biologics Limited - Ascenta Therapeutics, Inc. - Onconova Therapeutics, Inc. - Genexine, Inc. - Viventia Biotechnologies Inc. - Oncovir, Inc. - Gliknik, Inc. - Karyopharm Therapeutics, Inc. - Agonox - Tolero Pharmaceuticals, Inc. - AlphaMab Co., Ltd For more information visit http://www.researchandmarkets.com/research/wm...d_and_neck
CVM: 0.84 (-0.01), IMGN: 7.19 (unch), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), ONTX: 2.27 (-0.02), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), OXGN: 1.61 (+0.01), XLRN: 38.02 (+0.07), KPTI: 27.12 (-0.13), NVS: 102.20 (-0.17)
OXiGENE Announces Presentation of Phase 2 Data Confirming That Addition of Fosbretabulin to Bevacizumab Significantly Increases Progression-Free Survival in Recurrent Ovarian Cancer
GlobeNewswire - Mon Nov 10, 2:00AM CST
- Subgroup Analysis of GOG 186I Study Shows Benefit in Difficult-to-Treat Platinum-Resistant Patients -
OXGN: 1.61 (+0.01)
OXiGENE Down 5.8%, Shares Slide into the Red (OXGN)
Comtex SmarTrend(R) - Thu Nov 06, 10:09AM CST
OXiGENE (NASDAQ:OXGN) is one of today's worst performing low-priced stocks, down 5.8% to $2.27 on 1.3x average daily volume. Thus far today, OXiGENE has traded 783,000 shares, vs. average volume of 600,000 shares per day. The stock has underperformed the Dow (-5.8% to the Dow's 0.5%) and underperformed the S&P 500 (-5.8% to the S&P's 0.3%) during today's trading.
OXGN: 1.61 (+0.01)
OXiGENE Announces Presentation and Webcast at the 17th Annual BIO CEO & Investor Conference on February 10th
GlobeNewswire - Mon Jan 26, 3:15PM CST
OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel cancer therapeutics, announced that David Chaplin, Ph.D., president and chief executive officer, will provide a corporate overview at the 17th Annual BIO CEO & Investor conference on February 10, 2015. The presentation will take place at 10:30 a.m. ET at the Waldorf Astoria Hotel in New York City.
OXGN: 1.61 (+0.01)
Biotech Stock Mailbag: Aethlon Medical, Oxigene, Sarepta
at The Street - Fri Dec 05, 5:00AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care.
OXGN: 1.61 (+0.01), BMRN: 100.76 (+1.98), RNA: 18.65 (unch), SRPT: 12.76 (+0.11)
OXiGENE Announces Preclinical Poster Presentation on OXi4503 at Upcoming American Society of Hematology Meeting
GlobeNewswire - Thu Nov 20, 7:00AM CST
OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing novel cancer therapeutics, today announced that a poster presentation related to its clinical stage product candidate, OXi4503, will be presented at the American Society of Hematology (ASH) annual meeting taking place December 6-9, 2014 in San Francisco.
OXGN: 1.61 (+0.01)
OXiGENE Announces Issuance of European Patent for OXi4503 in Acute Myeloid Leukemia and other Myeloid Malignancies
GlobeNewswire - Mon Nov 17, 3:00PM CST
OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing novel cancer therapeutics, today announced that the company has been granted a patent by the European Patent Office related to its current clinical product candidate, OXi4503. The patent (EP 2219451 B1) is drawn to the use of OXi4503 in treating non-solid myeloid neoplasm, including acute myeloid leukemia (AML).
OXGN: 1.61 (+0.01)
Hot Stock: OXiGENE, Shares Drop 5.3% (OXGN)
Comtex SmarTrend(R) - Mon Nov 17, 2:41PM CST
OXiGENE (NASDAQ:OXGN) is one of today's worst performing low-priced stocks, down 5.3% to $1.88 on 1.7x average daily volume. Thus far today, OXiGENE has traded 1.3 million shares, vs. average volume of 816,000 shares per day. The stock has underperformed the Dow (-5.3% to the Dow's 0.0%) and underperformed the S&P 500 (-5.3% to the S&P's -0.0%) during today's trading.
OXGN: 1.61 (+0.01)
Which Chemotherapy Should OXiGENE Test Their Zybrestat+Avastin Combo Against?
Clinically Sound Investor - at Seeking Alpha - Mon Nov 17, 10:42AM CST
OXGN: 1.61 (+0.01)
OXiGENE: Q3 Earnings And Avastin Approval, Bull Thesis Reiterated
Trevor Lowenthal - at Seeking Alpha - Fri Nov 14, 3:20PM CST
OXGN: 1.61 (+0.01)
Oxigene: Why I Think This Risky Biotech Is A Speculative Buy
Daniel Ward - at Seeking Alpha - Fri Nov 14, 8:15AM CST
OXGN: 1.61 (+0.01)
OXiGENE (OXGN) CEO Dr. Dave Chaplin on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 12, 8:27PM CST
OXGN: 1.61 (+0.01)
OXiGENE (OXGN) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Wed Nov 12, 3:25PM CST
OXGN: 1.61 (+0.01)
OXiGENE beats by $0.06
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 3:05PM CST
OXGN: 1.61 (+0.01)
OXiGENE Reports Third Quarter 2014 Financial Results
GlobeNewswire - Wed Nov 12, 3:02PM CST
- Positive Data from the Phase 2 GOG 186I Study in Ovarian Cancer Presented at Major Conference -
OXGN: 1.61 (+0.01)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 8:18AM CST
ANV: 0.97 (-0.03), KEP: 20.67 (+0.11), RADA: 2.46 (+0.01), SEAS: 18.83 (+0.03), HPJ: 5.71 (+0.16), PLUG: 3.15 (unch), SUPN: 8.80 (+0.22), NBG: 1.61 (+0.18), GV: 2.45 (+0.02), OXGN: 1.61 (+0.01), NOAH: 21.59 (+0.72), FOSL: 98.44 (-0.30), AEO: 14.68 (-0.12), IBIO: 0.90 (+0.36), MTOR: 14.33 (+0.38), MLNX: 46.35 (+1.47), SUSQ: 13.48 (+0.01)
Oxigene Faces Challenges for Ovarian Cancer Drug Even With Encouraging Data
at The Street - Wed Nov 12, 4:12AM CST
An analysis of results from Oxigene's phase II study of fosbretabulin plus Avastin in recurrent ovarian cancer.
OXGN: 1.61 (+0.01), GSK: 47.94 (+1.99)
Update: OXiGENE Presents Zybrestat/Avastin Data, Bull Thesis Remains Intact
Trevor Lowenthal - at Seeking Alpha - Tue Nov 11, 4:56AM CST
OXGN: 1.61 (+0.01)
Stock to Watch: OXiGENE Down 6.9% (OXGN)
Comtex SmarTrend(R) - Mon Nov 10, 11:59AM CST
OXiGENE (NASDAQ:OXGN) is one of today's worst performing low-priced stocks, down 6.9% to $2.01 on 1.0x average daily volume. Thus far today, OXiGENE has traded 694,000 shares, vs. average volume of 663,000 shares per day. The stock has underperformed the Dow (-6.9% to the Dow's 0.2%) and underperformed the S&P 500 (-6.9% to the S&P's 0.3%) during today's trading.
OXGN: 1.61 (+0.01)
OxiGene presents Phase 2 data on fosbretabulin
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 11:31AM CST
OXGN: 1.61 (+0.01)
Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Pipeline Report 2014 - 32 Companies & 65 DRug Profiles
M2 - Mon Nov 10, 10:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/wml9ch/head_and_neck) has announced the addition of the "Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Shionogi & Co., Ltd. - Amgen Inc. - Eli Lilly and Company - GlaxoSmithKline plc - Celltrion, Inc. - Novartis AG - Eisai Co., Ltd. - ImmunoGen, Inc. - Santaris Pharma A/S - CEL-SCI Corporation - OXiGENE, Inc. - Takara Bio Inc. - Panacea Biotec Limited - PCI Biotech AS - Nanobiotix - Acceleron Pharma, Inc. - Virttu Biologics Limited - Ascenta Therapeutics, Inc. - Onconova Therapeutics, Inc. - Genexine, Inc. - Viventia Biotechnologies Inc. - Oncovir, Inc. - Gliknik, Inc. - Karyopharm Therapeutics, Inc. - Agonox - Tolero Pharmaceuticals, Inc. - AlphaMab Co., Ltd For more information visit http://www.researchandmarkets.com/research/wm...d_and_neck
CVM: 0.84 (-0.01), IMGN: 7.19 (unch), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), ONTX: 2.27 (-0.02), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), OXGN: 1.61 (+0.01), XLRN: 38.02 (+0.07), KPTI: 27.12 (-0.13), NVS: 102.20 (-0.17)
OXiGENE Announces Presentation of Phase 2 Data Confirming That Addition of Fosbretabulin to Bevacizumab Significantly Increases Progression-Free Survival in Recurrent Ovarian Cancer
GlobeNewswire - Mon Nov 10, 2:00AM CST
- Subgroup Analysis of GOG 186I Study Shows Benefit in Difficult-to-Treat Platinum-Resistant Patients -
OXGN: 1.61 (+0.01)
OXiGENE Down 5.8%, Shares Slide into the Red (OXGN)
Comtex SmarTrend(R) - Thu Nov 06, 10:09AM CST
OXiGENE (NASDAQ:OXGN) is one of today's worst performing low-priced stocks, down 5.8% to $2.27 on 1.3x average daily volume. Thus far today, OXiGENE has traded 783,000 shares, vs. average volume of 600,000 shares per day. The stock has underperformed the Dow (-5.8% to the Dow's 0.5%) and underperformed the S&P 500 (-5.8% to the S&P's 0.3%) during today's trading.
OXGN: 1.61 (+0.01)
